Journals / Eastern Journal of Medicine / 2018 / Cilt: 23 - Sayı: 3

Beta-fibrinogen 455 G/A and angiotensin converting enzyme ins/del polymorphisms in patients with lung cancer

Pages
160–167
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In both of the groups fibrinogen level was higher in AA genotype compared to GG and GA genotypes in both of the groups (p<0.05) As a result, it can be stated that β-fibrinogen -455 G/A and ACE I/D polymorphisms are not related with formation and prognosis of lung cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In our study we have investigated polymorphism due to base change occurring at -455 position of promoter region of β- fibrinogen synthesizing gene in lung cancer patients.
📊
Key Findings & Data:In addition, we have also investigated insertion/deletion (I/D) polymorphism in intron 16 of Angiotensin Converting Enzyme (ACE) gene, located on chromosome 17q23.
💡
Conclusion & Impact:In both of the groups fibrinogen level was higher in AA genotype compared to GG and GA genotypes in both of the groups (p<0.05) As a result, it can be stated that β-fibrinogen -455 G/A and ACE I/D polymorphisms are not related with formation and prognosis of lung cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

In our study we have investigated polymorphism due to base change occurring at -455 position of promoter region of β- fibrinogen synthesizing gene in lung cancer patients. In addition, we have also investigated insertion/deletion (I/D) polymorphism in intron 16 of Angiotensin Converting Enzyme (ACE) gene, located on chromosome 17q23. Aim of our study is to determine polymorphisms of β-fibrinogen -455 G/A and ACE I/D in patients with lung cancer and healthy control and to determine whether these polymorphisms contribute to the formation of lung cancer. In addition, we aimed to clarify whether β-fibrinogen -455 G/A polymorphism effect the level of fibrinogen synthesis in patients with lung cancer. Samples in our study was obtained from 100 patients with lung cancer and 100 healthy volu nteers. Plasma fibrinogen levels were measured with ELISA method. Polymorphism analyses were determined with PCR-reverse hybridization method. Results of our study revealed that fibrinogen levels of patients with lung cancer were significantly higher than healthy control group (p<0.01). No difference was determined for β-fibrinogen -455 G/A and ACE I/D polymorphisms between patients with lung cancer and healthy control group. In both of the groups fibrinogen level was higher in AA genotype compared to GG and GA genotypes in both of the groups (p<0.05) As a result, it can be stated that β-fibrinogen -455 G/A and ACE I/D polymorphisms are not related with formation and prognosis of lung cancer.

🔖

Cite This Article

ALP, H. H., UMUDUM, F. Z., BAKAN, E. (2018). Beta-fibrinogen 455 G/A and angiotensin converting enzyme ins/del polymorphisms in patients with lung cancer. Eastern Journal of Medicine, Cilt: 23 - Sayı: 3, 160–167. https://ajindex.com/articles/198812

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Cheng ZS, Ma RL, Tan WJ, Zhang L, Tan QY. Lack of association between ACE insertion/deletion polymorphism and lung cancer: A meta-analysis. J Renin-Angio-Aldo S 2015; 16: 453-158.
  2. Cheon KT, Choi KH, Lee HB, Park SK, Rhee YK, Lee YC. Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung 2000; 178: 351-360.
  3. Yaren A, Oztop I, Turgut S, Turgut G, Degirmencioglu S, Demirpence M. Angiotensinconverting enzyme gene polymorphism is associated with anemia in non-small-cell lung cancer. Exp Biol Med 2008; 233: 32-37.
  4. Nacak M, Nacak I, Sanli M, Ozkur M, Pektas M, Aynacioglu AS. Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey. Cancer genetics and cytogenetics 2010; 198: 22-26. Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 2004; 23: 317-329.
  5. Yoshiji H, Kuriyama S, Fukui H. Angiotensin-Iconverting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biology 2002; 23: 348- 356. Abali H, Güllü I, Haznedaroğlu I, Erman M, Tekuzman G. Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Medical Hypotheses 2002; 59: 344- 348. Kaufman KM, Kelly J, Gray-McGuire C, Asundi N, Yu H, Reid J, et al. Linkage analysis of angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and systemic lupus erythematosus. Molecular and cellular endocrinology 2001; 177: 81-85.
  6. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends in endocrinology and metabolism: TEM 2005; 16: 293-299.
  7. Stroth U, Unger T. The renin-angiotensin system and its receptors. Journal of cardiovascular pharmacology 1999; 33 Suppl 1: 21-28; discussion 41-43.
  8. Wang J, Han T, Chen X, Tang X. The correlation study of beta-fibrinogen gene polymorphisms and plasma fibrinogen concentration in patients with colorectal cancer. China Oncology 2015; 25: 807- 811. Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H. Clotting Factor Gene Polymorphisms and Colorectal Cancer Risk. J Clin Oncol 2011; 29: 1722-1727.
  9. Brown ET, Fuller GM. Detection of a complex that associates with the B beta fibrinogen G(- 455)-A polymorphism. Blood 1998; 92: 3286- 3293. Lu D, Chen X, Huang M, Xu B, Ding